Navigation Links
New Study Finds that Timing of Brand Activities is a Key Component of an Effective Global Branding Process for New Pharmaceutical Products
Date:3/4/2017

CHAPEL HILL, N.C., March 3, 2017 /PRNewswire/ -- Pharmaceutical companies struggle to create global branding that will work across geographies and affiliates.

The timing of brand activities is a key component of an effective global branding process that will work across geographies and affiliates, according to new research from consulting firm Best Practices, LLC.

In the study, participants favored initially handing over 7 of 8 key branding elements to affiliates during the Phase III Data to NDA Filing period. This timing allows for global and affiliates to create brand element alignment over consequent months, with both sides completing the handover in the next periods, Filing to Registration (42% complete) and Registration/Approval to Launch (58% complete).

The study, Best Practices in Global Branding for New Products: Creating an Effective Global Brand for New Products and Ensuring Alignment across Geographies and Affiliates, can help brand leaders more effectively navigate the global branding process to ensure a successful global launch of a new product. 

The study contains current insights from leading pharmaceutical companies on questions such as:

  • When are companies starting and finishing key global branding activities such as tradename identification, positioning, message development and brand personality?
  • What functional groups are leading these branding activities and who has sign-off responsibilities?
  • How do organizations ensure their global branding elements meet affiliates' needs?
  • How much are agencies utilized for the different branding activities?
  • What are the agency costs associated with positioning and message development?

The full 76-page report contains hundreds of benchmark metrics and dozens of narratives from veteran branding leaders to provide executives with the tools, tactics and techniques to help organizations develop a successful global branding program.

Review a complimentary summary of the study at http://www.best-in-class.com/rr1442.htm.

The report is based on an extensive primary research project involving 18 branding leaders from pharmaceutical organizations. Pharmaceutical leaders can use this study to see how their global branding process compares with industry trends and averages.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-study-finds-that-timing-of-brand-activities-is-a-key-component-of-an-effective-global-branding-process-for-new-pharmaceutical-products-300417924.html


'/>"/>
SOURCE Best Practices, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... ... June 18, 2019 , ... The ... for patients in the Bridgeville, PA area. Understanding the crippling effects patients experience ... Wayne DiBartola and Tyler Porco offer same-day oral sedation, nitrous oxide, and IV ...
(Date:6/16/2019)... ... , ... AVIE! MedSpa and Laser Center is proud to offer Vivace™ ... for achieving dramatic improvements to the texture and tightness of skin on any area ... with tiny needles, spurring vibrant new collagen growth for a wide range of complexion ...
(Date:6/16/2019)... ... June 15, 2019 , ... ... cell clinic offering state-of-the-art treatment with cutting-edge technology, has opened. , The ... the game-changing healing capabilities of regenerative medicine. , “Using the remarkable cutting-edge ...
Breaking Medicine Technology:
(Date:6/19/2019)... ... 19, 2019 , ... LifeLearn Animal Health launches PetInsuranceInfo.com, a new pet insurance ... isn’t, and the questions they need to ask prior to purchasing a policy. ... and find the coverage that meets their budget and pet’s health care needs. ...
(Date:6/18/2019)... , ... June 18, 2019 , ... ... addressing unmet needs in the field of urology, today announced that Aaron Berger, ... UroLift® Center of Excellence. The designation recognizes that Dr. Aaron Berger has achieved ...
(Date:6/16/2019)... ... June 16, 2019 , ... Ted Danson on CNBC will ... for the advancement of medical marijuana-based pharmaceuticals in an upcoming episode, scheduled to ... information. , With two investigational new drug applications already accepted by the FDA, ...
(Date:6/13/2019)... ... 13, 2019 , ... MMJ BioPharma Cultivation, a premier medical ... of understanding (MOU) with MMJ International Holdings to grow cannabis and supply active ... Cultivation will be supplying MMJIH with extracts from the marijuana plant to support ...
(Date:6/13/2019)... ... June 13, 2019 , ... Hard money lenders like ... hours and the funds can also be provided quickly. If the documentation and collateral ... lenders are able to avoid the federal oversight involved with a traditional lender, which ...
Breaking Medicine News(10 mins):